EU

Cadeler A/S and Eneti Inc. Announce Launch of Share Exchange Offer for All of The Outstanding Shares of Common Stock of Eneti Inc.

Retrieved on: 
Mardi, novembre 7, 2023
OSE, Business analyst, CADLR, NYSE, International, Vice, Thomas Cadell (publisher), Oslo Stock Exchange, Conference, Wind, Danish, Internet, Prospectus, Webcast, CET, CFO, EU, Letter, Cryptocurrency, Renewable energy, Flour, Broadcasting, Eneti

MONACO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cadeler A/S (OSE: CADLR) (“Cadeler”) and Eneti Inc. (NYSE: NETI) (“Eneti”), two offshore wind turbine and foundation installation companies, announce the commencement of a share exchange offer (the “Offer”) for all of the outstanding shares of common stock of Eneti.

Key Points: 
  • MONACO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cadeler A/S (OSE: CADLR) (“Cadeler”) and Eneti Inc. (NYSE: NETI) (“Eneti”), two offshore wind turbine and foundation installation companies, announce the commencement of a share exchange offer (the “Offer”) for all of the outstanding shares of common stock of Eneti.
  • The combined group will be named Cadeler, and be headquartered in Copenhagen, Denmark, with its shares to be listed on the New York Stock Exchange in addition to its current listing on the Oslo Stock Exchange.
  • The current CEO of Cadeler Mikkel Gleerup will continue as CEO after the combination, while Peter Brogaard Hansen will continue as CFO.
  • Mr. Andreas Sohmen-Pao, Chairman of Cadeler said: “This is a strategic transaction combining two leading offshore wind companies.

NANOBIOTIX Announces Closing of Global Offering

Retrieved on: 
Mardi, novembre 7, 2023
Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, Bloomberg, License, State Street, Guggenheim, Guggenheim Partners, Jefferies Group, Telephone, Form, Additional notification thresholds, Cancer, Patient, Security (finance), The 8th Floor, Floor, NANO, ADS, Madison Avenue, Private, Option, Attention, Prospectus, EU, Euronext

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points: 
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • Jefferies LLC, Leerink Partners and Guggenheim Securities acted as global coordinators and joint bookrunners for the Global Offering.
  • The ADSs (including the Additional ADSs) and Ordinary Shares offered in the Global Offering were offered pursuant to an effective shelf registration statement on Form F-3 (Registration No.
  • The Global Offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

NANOBIOTIX Announces Closing of Global Offering

Retrieved on: 
Mardi, novembre 7, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, Bloomberg, License, State Street, Guggenheim, Guggenheim Partners, Jefferies Group, Telephone, Form, Additive manufacturing file format, Cancer, Patient, Security (finance), The 8th Floor, Floor, NANO, ADS, Madison Avenue, Note, AMF, Private, Option, Attention, Prospectus, EU, Euronext

PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today (the “Closing”) of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordinary shares (the “Underwriters’ Option”) in the form of American Depositary Shares (“ADSs”).

Key Points: 
  • PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today (the “Closing”) of its global follow-on offering reserved to specified categories of investors, including after partial exercise by the underwriters of their option to purchase additional ordinary shares (the “Underwriters’ Option”) in the form of American Depositary Shares (“ADSs”).
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • Jefferies LLC, Leerink Partners and Guggenheim Securities acted as global coordinators and joint bookrunners for the Global Offering.
  • The Global Offering was made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

Robinhood Reports Third Quarter 2023 Results

Retrieved on: 
Mardi, novembre 7, 2023
Crypto, Adjustment, Active users, AUC, ARPU, SBC, MAU, Cryptocurrency, EBITDA, IRA, Fraud, Robinhood Markets, GAAP, Gold, Acquisition, Entrepreneurship, Growth, EPS, ETF, Net, Investment, Movement, Securities lending, EU, Bank, Financial services, Automotive industry, Video game, Beauty salon, Q3

MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today announced financial results for the third quarter of 2023, which ended September 30, 2023.

Key Points: 
  • MENLO PARK, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today announced financial results for the third quarter of 2023, which ended September 30, 2023.
  • Q3 2023 EPS of -$0.09 included -$0.11 per share impact from a regulatory accrual of $104 million.
  • Robinhood will host a conference call to discuss its results at 2 p.m. PT / 5 p.m.
  • Based on our Q3 2023 results, our expense outlook for 2023 has changed from our prior outlook at Q2 2023 earnings (August 2, 2023).

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023

Retrieved on: 
Mardi, novembre 7, 2023
European Free Trade Association, TPOXX, European Free Trade Association Surveillance Authority, Health Emergency Preparedness and Response Authority, European, EFTA, Conference, EU

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • $15 million - $18 million of these orders are targeted for delivery in 2023.
  • SIGA will host a conference call and webcast to provide a business update today, Tuesday, November 7, 2023, at 4:30 P.M.
  • Participants may access the call by dialing 1-888-886-7786 for domestic callers or 1-416-764-8658 for international callers.
  • The archived webcast will be available in the Events and Presentations section of the Company's website .

HSBC Continental Europe: Pre Stabilisation Notice

Retrieved on: 
Mardi, novembre 7, 2023
London, Sale, United Kingdom, Financial Conduct Authority, Financial services, Issuer, RNS, London Stock Exchange, Person, State, Exercise, Prospectus, Financial Services and Markets Act 2000, EEA, Finance, Investment, Greenshoe, Security (finance), EU

However, there is no assurance that the Stabilisation Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

Key Points: 
  • However, there is no assurance that the Stabilisation Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.
  • Any stabilisation action or over-allotment shall be conducted in accordance with all applicable laws and rules.
  • This announcement is not an offer of securities for sale into the United States.
  • RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

Seoul Robotics Partners with ALP.Lab To Enhance Safety on European Roadways With 3D Perception Technology

Retrieved on: 
Mardi, novembre 7, 2023
Research, Weather, Salzburg Research, Robotics, Business development, Pedestrian, Lidar, Software, Death, Congestion, City, Mobile laboratory, Partnership, Business, Kalamazoo bicycle crash, Safety, Perception, Road, Central Europe, Seoul Robotics, DACH, EU

The LiDAR systems provide detailed insights into accident-prone intersections and are currently being deployed in Salzburg, Austria.

Key Points: 
  • The LiDAR systems provide detailed insights into accident-prone intersections and are currently being deployed in Salzburg, Austria.
  • The European Union (EU) has set a goal of reducing overall road deaths to zero by 2050 .
  • Cyclists have had the greatest increase in serious crash-related injuries at 24%, with a high proportion of cyclist fatalities occurring at intersections.
  • In order to achieve the EU’s goal and save lives, Seoul Robotics and ALP.Lab developed a LiDAR-based system, powered by Seoul Robotics’ perception software, SENSR™, to better understand interactions between vulnerable road users and vehicles.

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Mardi, novembre 7, 2023
Temporal lobe epilepsy, FDA, CSL, Research, Sale, IND, SOD1, Food, Chief scientific officer, ALS, Fabry disease, Workforce, Acquisition, Phase, Neuroscience, Hand, Nobel Prize, Safety, ARD International Music Competition, Investment, France, Patient, Immunosuppression, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Management, Cryptocurrency, EU

and AMSTERDAM, Nov. 07, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2023 and highlighted recent progress across its business.

Key Points: 
  • and AMSTERDAM, Nov. 07, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2023 and highlighted recent progress across its business.
  • Screening and patient enrollment is expected to begin in the fourth quarter of 2023 with first patient dosing planned to occur in the first quarter of 2024.
  • The Company expects to initiate patient screening in the fourth quarter of 2023 with first patient dosing planned to occur in the first quarter of 2024.
  • AMT-191 for the treatment of Fabry disease – The Company expects to submit an IND in the fourth quarter of 2023 and to begin patient dosing in 2024.

Transaction in Own Shares

Retrieved on: 
Mardi, novembre 7, 2023
Listing Rules, Financial Services Act, Market abuse, Shell, Financial Services Act 2012, Goldman Sachs, European Union (Withdrawal Agreement) Act 2020, European Union (Withdrawal) Act 2018, Withdrawal, European, Brexit, EU

These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 2 November 2023.

Key Points: 
  • These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 2 November 2023.
  • In respect of this programme, Goldman Sachs International will make trading decisions in relation to the securities independently of the Company for a period from 2 November 2023 up to and including 26 January 2024.
  • The on-market limb will be effected within certain pre-set parameters and in accordance with the Company's general authority to repurchase shares on-market.
  • The off-market limb will be effected in accordance with the Company's general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein.

Ferrari N.V.: Announcement of the Fourth Tranche of the Multi-Year Share Repurchase Program

Retrieved on: 
Mardi, novembre 7, 2023
Capital market, Bank, NYSE, Regulation, Disclosure, Sell, Share repurchase, EXM, Market abuse, Cryptocurrency, Ferrari, EU

Under this agreement, purchases may continue during any closed periods of Ferrari in accordance with the Regulations.

Key Points: 
  • Under this agreement, purchases may continue during any closed periods of Ferrari in accordance with the Regulations.
  • Secondly, Ferrari has entered into an additional mandate with a primary financial institution whereunder Ferrari intends to instruct repurchases of shares for up to Euro 100 million to be executed on the NYSE.
  • The repurchase authority will expire on October 13, 2024 or until such authority is extended or renewed before such date.
  • Details of the repurchase transactions carried out under the Fourth Tranche shall be disclosed to the market as required by applicable regulation.